Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IL-13
Biotech
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the clinic.
James Waldron
Jan 2, 2026 9:05am
Windward pens $700M deal for Qyuns' immunology bispecific
Dec 22, 2025 7:40am
Apogee claims IL-13 antibody sets new eczema treatment standard
Jul 7, 2025 8:29am
Lilly shows lebrikizumab's long-term eczema benefit over 2 years
Oct 20, 2023 10:00am
